Antisense Oligonucleotide Service

Antisense Oligonucleotide Service

Baseceuticals is a leading biotechnology company which has expertise in providing antisense oligonucleotide service for customers worldwide based on our mature experimental platform. We hold advanced equipment, first-class technologies and experienced scientific researchers, which are ready to offer you the high-quality and professional services with the most reasonable price. Our service will begin at the free consultation to analyze the specific situation and propose the best strategies for your projects. Our dedicated researchers will provide the technical support during the entire process. We have confidence in offering the satisfactory service according to your various requirements and assist you in accelerating the project progress.

The antisense oligonucleotides are regarded as therapeutic agents to achieve the purpose of treatment of human diseases. The antisense oligonucleotide includes short and single-strand RNA or DNA which is composed of sugar rings linked by a phosphate backbones attaching to one of four bases. These single-strand RNA or DNA molecules bind to specific RNAs and alter protein expression. With the rapid development of antisense oligonucleotides technology, some antisense oligonucleotides are in clinical trials or come into clinical application. For example, the usage of fomivirsen (a compound that prevents the translation of the mRNA encoding for the main immediate early region proteins of cytomegalovirus) to treat cytomegalovirus-induced retinitis has been approved by FDA in 1998. A compound targeting apolipoprotein B100 named mipomersen had been allowed by the FDA in 2013 to cure the familial hypercholesterolemia.

Antisense oligonucleotides work through different mechanisms, which can be divided into two categories broadly to finish target manipulation, namely recruit RNase H for degradation and those do not. In the first situation, antisense oligonucleotides can medicate RNA degradation through RNase H. RNase H mediates RNA cleavage as directed by antisense oligonucleotides hybridization. For antisense oligonucleotides that do not recruit RNase H, they target mRNA to inhibit translation, modulate splicing and inhibit microRNAs.

Antisense oligonucleotide (ASO) mechanisms of action Fig.1 Antisense oligonucleotide (ASO) mechanisms of action

At Baseceuticals, multiple antisense oligonucleotide services are available based on the excellent platform. Our services include but not limited to the antisense oligonucleotide design and synthesis service, screening services such as efficacy and specificity screening. In addition, we provide customized antisense oligonucleotide services to meet the specific needs.

Baseceuticals is the premier company to provide the most excellent antisense oligonucleotide service based on the extensive experience in gene therapy. Once the project begins, our professional research team will serve you with one-to-one service to make sure every step is well-organized and update the research progress on time. We shall be very pleased to discuss the details of your project and potential to apply antisense oligonucleotide in gene silencing for therapy. Baseceuticals will be the reliable partner for your research. If you have questions about the antisense oligonucleotide service, please feel free to contact us at .


  1. DeVos, S. L., & Miller, T. M. (2013). Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA. Neurotherapeutics, 10(3), 486–497.
For research use only. Not intended for any clinical use.

Get in Touch

Please contact us if you have questions about our company, our products, or general enquiries.

Please use the form below.